Jump to content

ACT Biotech Inc

From Wikipedia, the free encyclopedia

ACT Biotech Inc is a San Francisco-based, privately held biopharmaceutical company focused on the development and commercialization of targeted cancer drugs.[1][2] It was founded in 2008.[3]

The Company's clinical stage pipeline includes:

Other pipeline products include an oral Aurora A and B kinase inhibitor at the pre-IND stage, and an ABL tyrosine kinase inhibitor targeting the T315I mutant enzyme in pre-clinical development.[5][6]

References

[edit]
  1. ^ a b "ACT BIOTECH Announces Positive Interim Phase 2 Results with Telatinib in First-line Gastric Cancer". 11 Oct 2010.
  2. ^ "ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare". 7 May 2008. Archived from the original on 25 October 2016. Retrieved 23 January 2018.
  3. ^ Leuty, Ron (February 19, 2013). "ACT Biotech co-founder Ali Fattaey makes tracks to Curis". San Francisco Business Times. Retrieved October 24, 2016.
  4. ^ "ACT Biotech Receives Orphan Drug Designation for Telatinib, an Orally Available and Highly Selective Kinase Inhibitor, in". 2 June 2010.
  5. ^ Jim Kling (1 April 2011). "ACT Biotech Inc". Medtech Insight. Retrieved 22 February 2023.
  6. ^ "biotickr". biotickr. Retrieved 2022-10-23.
[edit]